Lyell Immunopharma Ratios (2019-2026) | LYEL

Ratios Dec2019 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
EBT Margin (Quarter)
-2,377.82%-1,774.63%-1,673.10%-12,328.93%-101.59%-2,139,533.33%-23.42%-89,321.54%-224,596.30%-209,724.00%-403,261.54%-1,625,200.00%-347,415.38%-131,000.00%-1,783,881.82%-764,357.14%-548,300.00%-226,580.00%-2,082,800.00%-2,103,350.00%
EBIT Margin (Quarter)
-2,386.11%-1,784.43%-1,684.55%-12,400.72%-104.25%-2,214,566.67%-30.55%-96,240.00%-244,092.59%-236,156.00%-457,753.85%-1,852,500.00%-396,369.23%-148,544.12%-1,828,609.09%-819,528.57%-589,250.00%-248,353.33%-2,127,400.00%-2,213,050.00%
EBITDA Margin (Quarter)
-2,385.27%-1,779.06%-3,021.40%-13,222.60%-106.53%-2,396,633.33%-12.40%-97,290.77%-231,074.07%-198,620.00%-398,792.31%-2,032,566.67%-352,323.08%-127,723.53%-1,749,127.27%-747,542.86%-534,812.50%-258,013.33%-2,344,700.00%-1,220,200.00%
Operating Margin (Quarter)
-2,386.11%-1,784.43%-1,684.55%-12,400.72%-104.25%-2,214,566.67%-30.55%-96,240.00%-244,092.59%-236,156.00%-457,753.85%-1,852,500.00%-396,369.23%-148,544.12%-1,828,609.09%-819,528.57%-589,250.00%-248,353.33%-2,127,400.00%-2,213,050.00%
Net Margin (Quarter)
-2,377.82%-1,774.63%-1,673.10%-12,328.93%-101.59%-2,139,533.33%-23.42%-89,321.54%-224,596.30%-209,724.00%-403,261.54%-1,625,200.00%-347,415.38%-131,000.00%-1,783,881.82%-764,357.14%-548,300.00%-226,580.00%-2,082,800.00%-2,103,350.00%
FCF Margin (Quarter)
-2,221.99%461.45%-3,305.63%-8,672.51%-171.03%-1,329,800.00%-45.26%-71,703.08%-143,700.00%-150,620.00%-312,784.62%-1,401,533.33%-295,576.92%-103,238.24%-426,963.64%-784,185.71%-433,962.50%-190,926.67%-542,583.33%-1,929,950.00%
Efficiency
Assets Average (Quarter)
1,214.10M1,162.87M1,099.75M1,046.89M999.47M957.41M909.01M857.90M815.17M772.51M722.12M674.18M636.68M555.04M460.33M407.63M396.71M374.01M345.34M
Equity Average (Quarter)
343.95M1,004.21M958.13M905.52M874.65M844.03M826.64M808.54M760.34M717.21M676.26M629.05M584.83M548.60M456.76M359.67M317.72M314.02M288.66M260.93M
Invested Capital (Quarter)
1,021.96M986.47M929.79M881.25M868.04M820.03M833.25M783.83M736.86M697.57M654.95M603.16M566.50M530.70M382.82M336.52M298.92M329.12M248.20M273.67M
Asset Utilization Ratio (Quarter)
0.010.010.010.040.040.090.090.060.060.000.000.000.000.000.000.000.000.000.00
Leverage & Solvency
Equity Ratio (Quarter)
0.830.820.820.820.850.840.890.890.880.880.870.870.870.860.780.780.780.810.730.78
Valuation
Enterprise Value (Quarter)
-824.52M-618.92M-614.79M-613.91M-655.56M-648.13M-640.15M-612.77M-595.75M-575.43M-546.22M-526.30M-491.12M-440.55M-370.53M-301.18M-276.79M-319.62M-247.22M-254.02M
Return Ratios
Return on Sales (Quarter)
-0.24%-0.18%-0.17%-1.23%-0.01%-213.95%0.00%-8.93%-22.46%-20.97%-40.33%-162.52%-34.74%-13.10%-178.39%-76.44%-54.83%-22.66%-208.28%-210.34%
Return on Capital Employed (Quarter)
-17.90%-19.24%-21.53%-20.32%-23.18%-20.32%-20.61%-25.46%-25.93%-33.47%-34.80%-35.08%-36.00%-71.57%-86.04%-96.07%-93.99%-83.00%-83.11%
Return on Assets (Quarter)
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%
Return on Equity (Quarter)
-0.01%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%